Tag: Clinical Trial Phases clinical trial phases

Informed Consent Challenges in High-Risk Early Phase Studies

Posted on digi By digi

Informed Consent Challenges in High-Risk Early Phase Studies Addressing Consent Barriers in High-Risk First-in-Human and Early Clinical Trials Introduction Informed consent is a cornerstone of ethical clinical research, but its implementation becomes significantly more complex in high-risk Phase 1 trials. These early-stage studies often involve first-in-human (FIH) dosing, novel mechanisms, limited preclinical safety data, and…

Read More “Informed Consent Challenges in High-Risk Early Phase Studies” »

Phase 1 (Safety and Dosage)

Trial Registration, Protocol Transparency, and Results Disclosure in Phase 2

Posted on digi By digi

Trial Registration, Protocol Transparency, and Results Disclosure in Phase 2 Ensuring Transparency in Phase 2: Trial Registration, Protocol Disclosure, and Public Reporting Introduction In today’s regulatory and public environment, transparency in clinical trials is not optional—it is mandatory. Phase 2 trials must be registered on public platforms, key elements of their protocols disclosed, and results…

Read More “Trial Registration, Protocol Transparency, and Results Disclosure in Phase 2” »

Phase 2 (Efficacy and Side Effects)

Real-Time Data Monitoring Platforms for Phase 1 Trials

Posted on digi By digi

Real-Time Data Monitoring Platforms for Phase 1 Trials Transforming Early Trials with Real-Time Data Monitoring Technologies Introduction Phase 1 clinical trials are dynamic, fast-paced, and data-intensive. These early studies demand close oversight of safety signals, pharmacokinetic (PK) parameters, and operational compliance. Traditional data collection and monitoring methods—dependent on batch uploads, manual reviews, and delayed visibility—are…

Read More “Real-Time Data Monitoring Platforms for Phase 1 Trials” »

Phase 1 (Safety and Dosage)

IND Maintenance and Amendments During Phase 2

Posted on digi By digi

IND Maintenance and Amendments During Phase 2 How to Maintain and Amend an IND During Phase 2 Clinical Trials Introduction After an Investigational New Drug (IND) application is accepted by the U.S. FDA, it must be actively maintained throughout all clinical trial phases. During Phase 2, new data frequently emerge that may require updates to…

Read More “IND Maintenance and Amendments During Phase 2” »

Phase 2 (Efficacy and Side Effects)

Bridging from IV to Oral Formulations in Early Development

Posted on digi By digi

Bridging from IV to Oral Formulations in Early Development Strategies for Transitioning from Intravenous to Oral Formulations in Phase 1 Trials Introduction Many drug development programs begin with intravenous (IV) formulations in Phase 1 to ensure controlled delivery and avoid bioavailability uncertainties. However, most commercial drugs aim for oral delivery due to patient convenience and…

Read More “Bridging from IV to Oral Formulations in Early Development” »

Phase 1 (Safety and Dosage)

Global Regulatory Expectations for Phase 2 Trials (FDA, EMA, PMDA, CDSCO)

Posted on digi By digi

Global Regulatory Expectations for Phase 2 Trials (FDA, EMA, PMDA, CDSCO) Understanding Global Regulatory Requirements for Phase 2 Clinical Trials Introduction Phase 2 clinical trials represent a crucial stage in drug development where sponsors assess preliminary efficacy, confirm safety, and determine optimal dosing. Regulatory agencies around the world—FDA (US), EMA (Europe), PMDA (Japan), and CDSCO…

Read More “Global Regulatory Expectations for Phase 2 Trials (FDA, EMA, PMDA, CDSCO)” »

Phase 2 (Efficacy and Side Effects)

Microtracer and AMS Techniques in Early Human PK Studies

Posted on digi By digi

Microtracer and AMS Techniques in Early Human PK Studies Enhancing Early-Phase Pharmacokinetics with Microtracers and AMS Technology Introduction Obtaining precise and early pharmacokinetic (PK) data is essential to inform dose selection, metabolism, and safety strategies in Phase 1 clinical trials. Traditionally, human mass balance and absorption studies required high doses of radiolabeled compounds, posing ethical…

Read More “Microtracer and AMS Techniques in Early Human PK Studies” »

Phase 1 (Safety and Dosage)

Statistical Simulation Models in Dose Optimization

Posted on digi By digi

Statistical Simulation Models in Dose Optimization Using Statistical Simulation Models to Optimize Dosing in Phase 2 Trials Introduction In Phase 2 clinical trials, optimizing the dose is one of the most important objectives—balancing efficacy, safety, and pharmacologic parameters. Traditionally, dose selection relied on empirical observation and stepwise escalation. However, with increasing trial complexity and variability…

Read More “Statistical Simulation Models in Dose Optimization” »

Phase 2 (Efficacy and Side Effects)

Use of Phase 1 Data in NDA/BLA Submissions: What Regulators Look For

Posted on digi By digi

Use of Phase 1 Data in NDA/BLA Submissions: What Regulators Look For Leveraging Early Phase Data for Regulatory Success in NDA and BLA Filings Introduction Phase 1 clinical studies are traditionally viewed as safety and pharmacokinetics (PK)-focused investigations, but they also form the backbone of any successful New Drug Application (NDA) or Biologics License Application…

Read More “Use of Phase 1 Data in NDA/BLA Submissions: What Regulators Look For” »

Phase 1 (Safety and Dosage)

Go/No-Go Decision Criteria for Advancing to Phase 3

Posted on digi By digi

Go/No-Go Decision Criteria for Advancing to Phase 3 Establishing Go/No-Go Criteria for Phase 2 Trials: Making the Right Decision to Advance to Phase 3 Introduction One of the most critical junctures in drug development occurs at the end of a Phase 2 trial—deciding whether to advance a candidate to Phase 3. This decision, often referred…

Read More “Go/No-Go Decision Criteria for Advancing to Phase 3” »

Phase 2 (Efficacy and Side Effects)